Your browser doesn't support javascript.
loading
Validation of a commercially available test that enables the quantification of the numbers of CGG trinucleotide repeat expansion in FMR1 gene.
Lim, Grace X Y; Yeo, Minli; Koh, Yvonne Y; Winarni, Tri Indah; Rajan-Babu, Indhu-Shree; Chong, Samuel S; Faradz, Sultana M H; Guan, Ming.
Afiliação
  • Lim GX; The BioFactory Pte Ltd, Singapore, Singapore.
  • Yeo M; The BioFactory Pte Ltd, Singapore, Singapore.
  • Koh YY; The BioFactory Pte Ltd, Singapore, Singapore.
  • Winarni TI; Division of Human Genetics, Center for Biomedical Research, Faculty of Medicine, Diponegoro University, Semarang, Indonesia.
  • Rajan-Babu IS; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Chong SS; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Faradz SM; Khoo Teck Puat-National University Children's Medical Institute, National University Health System, Singapore, Singapore.
  • Guan M; Department of Laboratory Medicine, National University Hospital, Singapore, Singapore.
PLoS One ; 12(3): e0173279, 2017.
Article em En | MEDLINE | ID: mdl-28278294
In the present study, we evaluated a commercially available TP-PCR-based assay, the FastFraXTM FMR1 Sizing kit, as a test in quantifying the number of CGG repeats in the FMR1 gene. Based on testing with well characterized DNA samples from Coriell, the kit yielded size results within 3 repeats of those obtained by common consensus (n = 14), with the exception of one allele. Furthermore, based on data obtained using all Coriell samples with or without common consensus (n = 29), the Sizing kit was 97.5% in agreement with existing approaches. Additionally, the kit generated consistent size information in repeatability and reproducibility studies (CV 0.39% to 3.42%). Clinical performance was established with 198 archived clinical samples, yielding results of 100% sensitivity (95% CI, 91.03% to 100%) and 100% specificity (95% CI, 97.64% to 100%) in categorizing patient samples into the respective normal, intermediate, premutation and full mutation genotypes.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA / Expansão das Repetições de Trinucleotídeos / Proteína do X Frágil da Deficiência Intelectual / Síndrome do Cromossomo X Frágil / Mutação Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: DNA / Expansão das Repetições de Trinucleotídeos / Proteína do X Frágil da Deficiência Intelectual / Síndrome do Cromossomo X Frágil / Mutação Idioma: En Ano de publicação: 2017 Tipo de documento: Article